Lake Street analyst Brooks O'Neil believes the ruling yesterday in the case of Allergan (AGN) versus Imprimis Pharmaceuticals removes a "significant overhang" on shares of Harrow Health (HROW) and the entire compounding industry. Observers believed that if big pharma can use the Lanham Act to police compliance, as opposed to relying on government regulations, there could be serious implications for manufacturers of lower-cost, compounded medicines, O'Neil tells investors in a research note. He reiterates a Buy rating on Harrow Health with a $10 price target.